Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

Muhammad S. Beg; Andrew Brenner; Jasgit C. Sachdev; Mitesh J. Borad; Yoon‐Koo Kang; Jay Stoudemire; Susan Smith; Andreas G. Bader; Sinil Kim; David S. Hong

doi:10.1007/s10637-016-0407-y

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

Muhammad S. Beg(Southwestern Medical Center), Andrew Brenner(The University of Texas at San Antonio Health Science Center), Jasgit C. Sachdev(Scottsdale Research Institute (United States)), Mitesh J. Borad(Mayo Clinic in Arizona), Yoon‐Koo Kang(Asan Medical Center), Jay Stoudemire(Mirna Therapeutics (United States)), Susan Smith(Mirna Therapeutics (United States)), Andreas G. Bader(Mirna Therapeutics (United States)), Sinil Kim(Mirna Therapeutics (United States)), David S. Hong(The University of Texas MD Anderson Cancer Center)

Investigational New Drugs

December 5, 2016

10.1007/s10637-016-0407-y

Cited by 880Open Access

Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis